We report on a study of 6 cases of Necrotising Sarcoidal Granulomatosis (NSG) and details of another problem case illustrating the difficulties of classification. We have compared the clinical and pathological features with those of sarcoidosis, Wegener's Granulomatosis (WG), Churg Strauss Granulomatosis (CSG), Pulmonary Hyalinizing Granuloma (PHG) and various metal lung diseases. We distinguish NSG from sarcoidosis, in particular by the prominence of vasculitis, necrosis and the rarity of extrapulmonary manifestations, but accept that problem cases can occur. We see no difficulty in separating NSG from CSG, PHG and metal lung granulomatous diseases, but on occasion WG may cause considerable difficulty. For the present NSG is best regarded as a distinct entity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systemic Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues.
Pediatr Blood Cancer
January 2025
Pediatrics Department, Jean Verdier Hospital, APHP, Bondy, France.
Background: Systemic inflammatory diseases (SIDs) have been reported in patients with sickle cell disease (SCD), but clinical data in children are scarce.
Objectives: To identify clinical and laboratory features at diagnosis of SID in children with SCD and to describe their evolution.
Methods: Data from children with SCD and SIDs were retrospectively collected in a French multicenter study from 1991 to 2018.
Cytomorphological diagnosis of sarcoidosis using EBUS-TBNA in a tuberculosis-endemic region.
Rev Esp Patol
January 2025
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Background: Sarcoidosis, a granulomatous inflammatory disease, exhibits diverse clinical manifestations, often affecting multiple organs. Diagnostic challenges arise due to its similarities with tuberculosis, particularly in high-burden areas. Differentiating between the two relies on clinical judgment, laboratory tests, imaging, and invasive procedures.
View Article and Find Full Text PDFComparison of long-term outcomes in patients with cardiac sarcoidosis treated with different immunosuppressive drugs.
Am J Cardiovasc Dis
December 2024
Division of Cardiovascular Medicine, SSM-Saint Louis University Hospital St. Louis, MO, USA.
Background: We compared long-term clinical outcomes between patients with cardiac sarcoidosis (CS) who received no treatment (NT), steroid treatment (ST), disease-modifying anti-rheumatic drugs (DMARDs), or tumor necrosis factor alpha inhibitors (TNF).
Methods: Patients from SSM healthcare system's data warehouse were identified using ICD codes. Inclusion criteria included at least 6 months of follow-up.
Clinical Experience with TNF Inhibition and Longitudinal Image Monitoring in Osseous Sarcoidosis.
J Clin Rheumatol
January 2025
From the Department of Rheumatology, Brooke Army Medical Center, Fort Sam Houston, TX.
Background: In this case series, we present longitudinal imaging surveillance of 6 cases of osseous sarcoidosis, each of which was effectively treated with tumor necrosis factor (TNF) inhibition.
Methods: We identified 6 patients from Brooke Army Medical Center with osseous sarcoidosis, who were treated with TNF inhibition and followed with longitudinal imaging studies. Cases of osseous sarcoidosis were defined as having pathologic evidence of noncaseating granulomas on bone biopsy and evidence of osseous lesions on imaging attributable to sarcoidosis by the radiologist, treating clinician, and reviewer.
Amyotrophic lateral sclerosis in a patient with chronic lymphocytic leukaemia and drug related sarcoid-like reaction.
BMC Neurol
January 2025
Department of Neurology, Wessex Neurological Centre, University Hospital Southampton, Southampton, UK.
Article Synopsis
- Sarcoid-like reaction (SLR) is an immune response affecting lymph nodes and organs, which doesn't fulfill the criteria for systemic sarcoidosis, and can be associated with certain diseases like Chronic lymphocytic leukaemia (CLL) and Amyotrophic lateral sclerosis (ALS).
- A 60-year-old male patient with treated CLL developed ALS symptoms following exposure to Venetoclax and Rituximab, presenting with rashes and weakness that progressed over a year.
- Diagnosis complications included atypical signs and symptoms, leading to misdiagnosis of neurosarcoidosis and challenges in treatment, despite initial interventions with prednisolone and infliximab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!